

RESEARCH ARTICLE

Epidemiology and Resistance Patterns of Bacterial and Fungal Colonization of Biliary Plastic Stents: A Prospective Cohort Study

Christoph Lübbert^{1,2,3*}, Karolin Wendt², Jürgen Feisthammel¹, Annette Moter⁴, Norman Lippmann^{3,5}, Thilo Busch⁶, Joachim Mössner¹, Albrecht Hoffmeister¹, Arne C. Rodloff^{3,5}

1 Interdisciplinary Endoscopy Unit, Department of Gastroenterology and Rheumatology, Leipzig University Hospital, Liebigstr. 20, D-04103 Leipzig, Germany, **2** Division of Infectious Diseases and Tropical Medicine, Department of Gastroenterology and Rheumatology, Leipzig University Hospital, Liebigstr. 20, D-04103 Leipzig, Germany, **3** Interdisciplinary Center for Infectious Diseases, Leipzig University Hospital, D-04103 Leipzig, Germany, **4** Biofilm Center, German Heart Institute (Deutsches Herzzentrum Berlin, DHZB), Hindenburgdamm 30, D-12203 Berlin, Germany, **5** Institute for Medical Microbiology and Epidemiology of Infectious Diseases, Leipzig University Hospital, Liebigstr. 21, D-04103 Leipzig, Germany, **6** Department of Anaesthesiology and Intensive Care Medicine, Leipzig University Hospital, Liebigstr. 20, D-04103 Leipzig, Germany

* christoph.luebbert@medizin.uni-leipzig.de



OPEN ACCESS

Citation: Lübbert C, Wendt K, Feisthammel J, Moter A, Lippmann N, Busch T, et al. (2016) Epidemiology and Resistance Patterns of Bacterial and Fungal Colonization of Biliary Plastic Stents: A Prospective Cohort Study. PLoS ONE 11(5): e0155479. doi:10.1371/journal.pone.0155479

Editor: Gianfranco D. Alpini, Texas A&M University, UNITED STATES

Received: March 10, 2016

Accepted: April 29, 2016

Published: May 12, 2016

Copyright: © 2016 Lübbert et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The whole study data base is made available for download in the Supporting information files.

Funding: The authors acknowledge support from the German Research Foundation (DFG) and Universität Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Background

Plastic stents used for the treatment of biliary obstruction will become occluded over time due to microbial colonization and formation of biofilms. Treatment of stent-associated cholangitis is often not effective because of inappropriate use of antimicrobial agents or antimicrobial resistance. We aimed to assess the current bacterial and fungal etiology of stent-associated biofilms, with particular emphasis on antimicrobial resistance.

Methods

Patients with biliary strictures requiring endoscopic stent placement were prospectively enrolled. After the retrieval of stents, biofilms were disrupted by sonication, microorganisms were cultured, and isolates were identified by matrix-associated laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry and/or biochemical typing. Finally, minimum inhibitory concentrations (MICs) were determined for various antimicrobial agents. Selected stents were further analyzed by fluorescence in situ hybridization (FISH).

Results

Among 120 patients (62.5% males, median age 64 years) with biliary strictures (35% malignant, 65% benign), 113 double pigtail polyurethane and 100 straight polyethylene stents were analyzed after a median indwelling time of 63 days (range, 1–1274 days). The stent occlusion rate was 11.5% and 13%, respectively, being associated with a significantly increased risk of cholangitis (38.5% vs. 9.1%, $P < 0.001$). Ninety-five different bacterial and

13 fungal species were detected; polymicrobial colonization predominated (95.8% vs. 4.2%, $P < 0.001$). Enterococci (79.3%), *Enterobacteriaceae* (73.7%), and *Candida* spp. (55.9%) were the leading pathogens. *Candida* species were more frequent in patients previously receiving prolonged antibiotic therapy (63% vs. 46.7%, $P = 0.023$). Vancomycin-resistant enterococci accounted for 13.7%, extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae* with co-resistance to ciprofloxacin accounted for 13.9%, and azole-resistant *Candida* spp. accounted for 32.9% of the respective isolates.

Conclusions

Enterococci and *Candida* species play an important role in the microbial colonization of biliary stents. Therefore, empirical antimicrobial treatment of stent-associated cholangitis should be guided toward enterococci, *Enterobacteriaceae*, streptococci, anaerobes, and *Candida*. To determine causative pathogens, an accurate microbiological analysis of the extracted stent(s) may be helpful.

Introduction

Obstruction of the biliary system by malignancies, anastomotic stenosis after liver transplantation, chronic pancreatitis, or gallstones that are not immediately extractable endoscopically prevents the drainage of bile fluids from the liver and gall bladder to the small intestine and results in obstructive jaundice [1–3]. Gold standard for palliative treatment of an obstructed bile duct is the insertion of a stent by endoscopic retrograde cholangiopancreatography (ERCP) to restore bile fluid drainage [2,3]. However, sooner or later, biliary stents become colonized by microorganisms and ultimately occluded by a sludge (Fig 1) composed of bacteria, fungi, proteins, calcium bilirubinate, calcium palmitate, cholesterol, and plant fibers, leading to recurrent cholestasis or cholangitis [1,4–9]. The risk for stent occlusion depends on the indwelling time of the stent [1–3,8,10]. According to available studies, median patency of plastic stents ranges between 70 and 126 days [2,3,8,10]. Therefore, most endoscopy units perform stent exchanges at a programmed interval of three months to avoid stent occlusion [2,10,11]. Self-expanding metal stents may double the patency time as compared to straight polyethylene stents [12]. The application of antibiotics, such as ofloxacin, alone or in combination with ursodeoxycholic acid, has failed in preventing stent occlusion [13].

A broad range of studies suggest that bacterial adhesion to artificial surfaces, resulting in the formation of biofilms, drives sludge development ahead [10,14–22]. A biofilm is a structured consortium of microorganisms embedded in a self-produced polymer matrix consisting of polysaccharides, proteins, and deoxyribonucleic acid (DNA). This consortium can consist of one or more species living in a sociomicrobiological way [21]. Bacterial biofilms predispose for chronic infections because indwelling microorganisms show increased tolerance to antibiotics and disinfectant chemicals as well as resist phagocytosis and other components of the body's defense system [21]. In a pioneering study published in 1988, Leung et al. perfused biliary stents with either bacterially contaminated or sterile bile fluid [14]. Scanning electron microscopy revealed a dense layer of bacteria and amorphous material on the surface of the stents which were perfused with bacterially contaminated bile. In contrast, this phenomenon was not observed in experiments using sterile bile only [14].




Fig 1. Endoscopic extraction of occluded biliary polyethylene stents (double stenting in a 52 year-old patient with biliary stenosis due to chronic pancreatitis).

doi:10.1371/journal.pone.0155479.g001

The clinical management of biofilm-associated infections is challenging because the microbes in the stent are not generally amenable to eradication employing antimicrobial chemotherapy [1]. Thus, the occluded device must be replaced endoscopically, which requires an elaborate and, from the perspective of the patient, stressful procedure. Although stent replacement may be repeated several times, stent lifetime tends to decrease progressively, presumably because relevant microbes that have adapted to the stent niche accumulate within the bile duct [1]. Biofilms developing on biliary stents usually consist of a broad and diverse spectrum of mixed microbial communities [1,17,19]. However, many bacteria of the gut microbiota may not presently be cultivated by standard laboratory procedures. Thus, existing data on biliary stent microbial communities may be biased and incomplete [1]. Notably, even available information on culturable bacteria is not static and shows a recent trend toward pathogens such as extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*, enterococci, and *Candida* species [10,23–28]. Thus, standard antimicrobial therapy concepts for patients with cholangitis, which mainly target sensitive *Enterobacteriaceae* and anaerobes, need to be reevaluated [25–28].

We performed this prospective cohort study to determine the current bacterial and fungal etiology of biofilm formation in biliary stents, with particular emphasis on antibiotic therapy and thereby exerted selective pressure. A further objective was to assess the dynamics of pathogens and the epidemiology of antimicrobial resistance compared to what was found in previous studies [10,14,17,19,20,23,24].

Patients and Methods

Study population and study design

From June 2013 to March 2015, 120 patients with biliary strictures and elective or emergency stent exchanges were consecutively enrolled. Stent exchanges were performed at the interdisciplinary endoscopy unit of the Leipzig University Hospital (Leipzig, Germany) by experienced endoscopic examiners (personal record of >250 ERCPs).

Ethics approval

The study was performed in accordance with the ethical guidelines of the 1964 Declaration of Helsinki and was approved by the local ethics committee (University of Leipzig, register no. 059-13-11032013). As the study did not modify patient management, and as the data were processed anonymously, the need for informed consent was waived according to the ethics committee approval.

Interventional endoscopic procedure

ERC was performed using standard videoduodenoscopes of the Fujinon ED-530 series (Fujinon, Japan). First, the position of the indwelling biliary stent(s) was documented by direct endoscopic visualization and x-ray. Afterwards, (a) stent(s) was (were) grasped by a snare or forceps and then extracted by complete retraction of the endoscope through the stomach, the esophagus, the pharynx, and the oral cavity. Subsequently, a 5F catheter was inserted into the biliary tract, and contrast fluid was injected. Depending on the results of previous and current cholangiograms, either (a) new stent(s) was (were) inserted, or the stent therapy was ended. The caliber of subsequent stent placements varied between 8F and 11.5F, as in the previous intervention.

Stent characteristics and stent preparation

All extracted stents were made of either polyethylene (straight stents from Cook Medical, Ireland, or from Boston Scientific, USA) or polyurethane (double pigtail stents from Optimed, Germany). To minimize the risk of contamination, and to provide the best possible pre-analytic conditions, 3–4 centimeters of the distal end of the extracted stent(s), previously located in the intestinal lumen, were removed using sterile scissors, and immediately thereafter, stents were immersed in a sterile nutrient solution (Brain Heart Infusion Broth; Merck, Germany). Transport to the microbiology laboratory was performed on the same day, where the stent(s) was (were) worked up according to a standardized protocol. In patients with multi-stenting, only one stent was submitted for microbiological analysis.

Definition of stent occlusion

Before starting the sonication process, an assessment of the drainage function of the stent was carried out in the microbiology laboratory. Hereby, encrusted sludge completely narrowing the stent lumen was defined as inner stent occlusion, as described previously [10].

Sonication process

In the microbiology laboratory, the prepared stent was put into a sterile container (Bandelin, Germany) and completely covered with 50 ml of sterile Ringer's solution. To disrupt the bio-film on the inner surface of the stent, the specimen was vortexed for 30 seconds and subsequently exposed to low-frequency (40 kHz) ultrasound for 15 minutes, as described previously [10,29,30]. Sonication was performed in an ultrasound bath specially designed for microbiological analysis (BactoSonic[®]; Bandelin, Germany). Thereafter, the container was vortexed again for 30 seconds.

Microbiological analysis

Aliquots of the sonication fluid were cultivated on conventional solid media (sheep blood agar, blood agar, chocolate agar, Esculin agar, Endo agar, Columbia agar with and without gentamicin supplementation, CHROMagar[™] ESBL, and Sabouraud agar) and incubated in aerobic and

anaerobic atmospheres at 37°C (Heraeus Incubator Series 6000; Thermo Scientific, Germany), as described previously [10]. Aerobic cultures were incubated for at least 48 hours, and anaerobic cultures for 96 hours. All bacterial isolates were identified using a matrix-associated laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF MS; bioMérieux, France). Fungal isolates were submitted to a commercially available assimilation test (ID 32 C yeast identification system; bioMérieux, France) for species identification.

Antimicrobial susceptibility testing

Depending on the Gram stain nature of the bacterial isolates, minimum inhibitory concentrations (MICs) were established according to International Organization for Standardization (ISO) 20776–1 for the following antimicrobial agents: penicillin G, ampicillin, oxacillin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, cefuroxime, cefotaxime, ceftazidime, imipenem, meropenem, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, erythromycin, clindamycin, vancomycin, teicoplanin, rifampicin, linezolid, daptomycin, doxycycline, trimethoprim/sulfamethoxazole, fosfomycin, colistin, and metronidazole. Tigecycline was tested using gradient strips (Etest[®]; bioMérieux, France). E-tests were also used for fungal isolates determining MICs for amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and caspofungin. Susceptibilities were assessed using breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST, www.eucast.org, 2015 edition) [31]. Phenotypic ESBL production was confirmed using appropriate E-tests (bioMérieux, France), as described previously [32].

Visualization of biofilm formation

In selected cases, biofilms were visualized by fluorescence in situ hybridization (FISH) (Fig 2) in the Biofilm Center of the German Heart Institute (Berlin, Germany), as described previously [33,34].

Blood cultures

Blood cultures were collected only in patients presenting with acute cholangitis or general signs of infection.

Statistical analysis

Statistical analysis was performed using SPSS for Windows (SPSS 20.0, IBM Corporation, Armonk, New York, USA). Numerical variables were summarized as medians, and categorical variables were given as frequencies or proportions. Confidence intervals (CI) for frequencies were calculated based on binomial distribution. Categorical data were analyzed by the chi-square test or Fisher's exact test. For the comparison of two independent groups, the nonparametric Mann-Whitney U test was used. Independent predictors for the occurrence of enterococci or *Candida* species were identified using multiple logistic regression. For comparing the time-dependent persistence of pathogens, the log-rank test was applied. P values (two-sided) of <0.05 were considered statistically significant.

Results

Patients and stent characteristics

One-hundred and twenty patients (62.5% males, 37.5% females, median age 64 years) with biliary strictures (35% with malignant strictures, 20.8% after liver transplantation, 18.3% due to gallstones, 9.2% due to chronic pancreatitis, 16.7% due to other reasons) requiring endoscopic




Fig 2. Presence of biofilm formation on a biliary polyethylene stent in a 62-year-old liver transplant recipient with anastomotic bile duct stenosis, visualized by fluorescence in situ hybridization (FISH). Using cultures, *Enterococcus faecalis* and *Escherichia coli* were detected.

doi:10.1371/journal.pone.0155479.g002

stent placement previously were prospectively enrolled in the study (Table 1). Preventive stent replacements accounted for 60.6% (129/213) of the procedures. Forty of 120 patients (33.3%) had repeating stenting procedures.

In these patients, 213 biliary stents (113 double pigtail stents, 100 straight plastic stents) were microbiologically analyzed after endoscopic retrieval (Fig 3). The median time of biliary stent placement was 63 days (range, 1–1274 days). The stent occlusion rate was 11.5% (13/113; 95% CI: 6.3% to 18.9%) in double pigtail stents, and it was 13% (13/100; 95% CI: 7.1% to 21.2%) in straight polyethylene stents. The analysis of the laboratory markers at baseline revealed a statistically significant difference only for alkaline phosphatase (AP) values ($P = 0.007$), presumably due to a slightly better drainage function of straight stents compared to double pigtail stents.

The clinical cholangitis rate (defined by the occurrence of fever, abdominal pain, jaundice, pus coming out of the papilla) was 20% (24/120; 95% CI: 13.3% to 28.3%). Three patients had multiple cholangitis episodes due to repeating stenting procedures. The risk of cholangitis was significantly higher in patients with stent occlusion (38.5% vs. 9.1%, $P < 0.001$). Eighty-six of the 120 patients (71.7%) received antibiotic treatments during stent insertion, mainly

Table 1. Baseline characteristics of the patients and stents.

Number of patients	120		
Median age in years (range)	64 (7–91)		
Male sex (%)	75 (62.5%)		
Reason for stent therapy			
Malignant disease (%)	42 (35%)		
Cholangiocarcinoma (%)	26 (21.7%)		
Pancreatic cancer (%)	6 (5%)		
Other malignancy (%)	10 (8.3%)		
Benign disease (%)	78 (65%)		
Anastomotic stenosis after liver transplantation (LTx) (%)	25 (20.8%)		
Choledocholithiasis (%)	22 (18.3%)		
Chronic pancreatitis (%)	11 (9.2%)		
Idiopathic biliary stricture (%)	11 (9.2%)		
Biliary leakage (%)	5 (4.2%)		
Other reasons (%)	4 (3.3%)		
Antibiotic therapy			
Ceftriaxone	38 (31.7%)		
Ciprofloxacin	34 (28.3%)		
Metronidazole	31 (25.8%)		
Piperacillin/tazobactam	31 (25.8%)		
Other agents	69 (65.8%)		
Clinical outcomes during the study period			
Death due to biliary infection (%)	5 (4.2%)		
Death due to underlying disease (%)	24 (20%)		
Death due to other reasons (%)	9 (7.5%)		
Total number of biliary stents	213		
Type of stent (material)	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
Number	113	100	n/a
Indwelling time in days (range)	64 (3–1202)	58 (1–1274)	0.559
Number of treatment episodes with multiple stenting	47	35	0.324
Stent occlusion rate (%)	13/113 (11.5%)	13/100 (13%)	0.739
Signs of cholangitis (fever, abdominal pain, jaundice, pus coming out of the papilla) (%)	14/113 (12.4%)	13/100 (13%)	0.894
Median laboratory parameters at baseline (normal range)			
Bilirubin ($\mu\text{mol/L}$; <17.1)	13.1	12.25	0.952
ALT ($\mu\text{kat/L}$; 0.17–0.85)	0.64	0.59	0.859
AST ($\mu\text{kat/L}$; 0.17–0.85)	0.74	0.58	0.160
AP ($\mu\text{kat/L}$; 0.58–2.15)	3.61	2.44	0.007
GGT ($\mu\text{kat/L}$; 0.17–1.19)	4.71	3.79	0.071
C-reactive protein (CRP) (mg/L; <5)	17.45	18.35	0.530
WBC (GPT/L; 3.5–9.8)	6.6	7.5	0.100

Abbreviations: ALT = alanine transaminase; AP = alkaline phosphatase; AST = aspartate transaminase; GGT = gamma-glutamyl transferase; WBC = white blood cells; n/a = not applicable

doi:10.1371/journal.pone.0155479.t001




Fig 3. Overview of microbiological results of cultures from sonicated stent fluids. Polymicrobial colonization of biliary stents (95.8%) was significantly more common than single microbial colonization (4.2%, $P < 0.001$) was.

doi:10.1371/journal.pone.0155479.g003

ceftriaxone (31.7%), ciprofloxacin (28.3%), metronidazole (25.8%), or piperacillin/tazobactam (25.8%), including combinations and sequential treatments. In patients with positive blood cultures for *Candida* species, antifungal therapy with either fluconazole, voriconazole, anidulafungin or liposomal amphotericin B was administered according to the results of the microbiological susceptibility testing.

Detection of bacteria and fungi

All endoscopically retrieved stents showed microbial colonization, even after an indwelling time of just one day. A total of 95 different bacterial and 13 different fungal species could be detected (Table 2).

Up to seven different species were detected on a single stent (Fig 4). Polymicrobial colonization (95.8%; 95% CI: 92.1% to 98%) was significantly more common than monomicrobial colonization (4.2%; 95% CI: 2% to 7.9%) was ($P < 0.001$). Enterococci were detected in 79.3% (169/213; 95% CI: 73.3% to 84.6%) of all stents, *Enterobacteriaceae* in 73.7% (157/213; 95% CI: 67.3% to 79.5%), streptococci in 31.5% (67/213; 95% CI: 25.3% to 38.2%), anaerobes in 23.5% (50/213; 95% CI: 18% to 29.7%), and staphylococci in 11.3% (24/213; 95% CI: 7.4% to 16.3%). In 55.9% (119/213; 95% CI: 48.9% to 62.6%) of all cases, *Candida* species were involved. Species identification revealed *Enterococcus faecalis* as the most common organism (50.2% of all stents), followed by *Candida albicans* (48.4%), *Escherichia coli* (41.7%), *Enterococcus faecium* (29.6%), *Streptococcus anginosus* (16.9%), *Enterobacter cloacae* (14.6%), *Klebsiella oxytoca* (11.3%), and *Candida glabrata* (10.8%).

In patients with repeating stenting procedures, a clear tendency toward the establishment of the same microbial flora on consecutive stents could be demonstrated, with a concordance rate of 84% for *Enterococcus faecalis*, 83% for *Candida albicans*, 72% for *Escherichia coli*, and 60% for *Enterococcus faecium* as the most common pathogens.

The microbiological species analysis revealed no significant difference between the microbial colonization of either polyethylene or polyurethane stents, regardless of their diameters, except for *Escherichia coli* ($P = 0.030$). Further statistically significant differences were found for colonization with *Candida* species (67.1% vs. 49.6%, $P = 0.015$), viridans group streptococci

Table 2. Spectrum of microorganisms* isolated from biliary stents.

Bacteria			
Gram-positive species	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
<i>Enterococcus faecalis</i>	56/113 (49.6%)	51/100 (51%)	0.834
<i>Enterococcus faecium</i>	37/113 (32.7%)	26/100 (26%)	0.282
<i>Enterococcus casseliflavus</i>	12/113 (10.6%)	5/100 (5%)	0.204
<i>Enterococcus avium</i>	10/113 (8.8%)	5/100 (5%)	0.224
<i>Enterococcus gallinarum</i>	8/113 (7.1%)	3/100 (3%)	0.224
Enterococci (other species)	2/113 (1.8%)	4/100 (4%)	0.423
<i>Streptococcus anginosus</i>	20/113 (17.7%)	16/100 (16%)	0.741
<i>Streptococcus parasanguinis</i>	5/113 (4.4%)	6/100 (6%)	0.604
<i>Streptococcus oralis/mitis</i>	3/113 (2.7%)	7/100 (7%)	0.195
<i>Streptococcus constellatus</i>	4/113 (3.5%)	1/100 (1%)	0.374
Streptococci (other species)	8/113 (7.1%)	7/100 (7%)	0.982
<i>Staphylococcus aureus</i>	2/113 (1.8%)	3/100 (3%)	0.667
<i>Staphylococcus epidermidis</i>	5/113 (4.4%)	5/100 (5%)	1.000
<i>Staphylococcus haemolyticus</i>	2/113 (1.8%)	4/100 (4%)	0.423
Staphylococci (other species)	0/113 (0%)	3/100 (3%)	0.102
Others	10/113 (8.8%)	8/100 (8%)	0.824
Gram-negative species	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
<i>Escherichia coli</i>	55/113 (48.7%)	34/100 (34%)	0.030
<i>Enterobacter cloacae</i>	16/113 (14.2%)	15/100 (15%)	0.862
<i>Klebsiella oxytoca</i>	14/113 (12.4%)	10/100 (10%)	0.582
<i>Klebsiella pneumoniae</i>	9/113 (8%)	11/100 (11%)	0.448
<i>Citrobacter spp.</i>	8/113 (7.1%)	6/100 (6%)	0.751
<i>Hafnia alvei</i>	7/113 (6.2%)	4/100 (4%)	0.470
<i>Pseudomonas aeruginosa</i>	6/113 (5.3%)	6/100 (6%)	0.827
<i>Proteus vulgaris</i>	5/113 (4.4%)	6/100 (6%)	0.604
<i>Proteus mirabilis</i>	5/113 (4.4%)	2/100 (2%)	0.452
<i>Morganella morganii</i>	2/113 (1.8%)	4/100 (4%)	0.423
Others	13/113 (11.5%)	16/100 (16%)	0.340
Anaerobes	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
<i>Bacteroides spp.</i>	11/113 (9.7%)	6/100 (6%)	0.316
<i>Prevotella spp.</i>	6/113 (5.3%)	7/100 (7%)	0.607
<i>Veillonella spp.</i>	4/113 (3.5%)	1/100 (1%)	0.374
Others	8/113 (7.1%)	7/100 (7%)	0.982
Fungi	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
<i>Candida albicans</i>	55/113 (48.7%)	48/100 (48%)	0.922
<i>Candida glabrata</i>	13/113 (11.5%)	10/100 (10%)	0.724
<i>Candida kefyr</i>	5/113 (4.4%)	0/100 (0%)	0.062
<i>Candida tropicalis</i>	1/113 (0.9%)	4/100 (4%)	0.189
<i>Candida</i> (other species)	6/113 (5.3%)	4/100 (4%)	0.753
Others	3/113 (2.7%)	1/100 (1%)	0.624
Multi-drug resistant species	Double pigtail stents (polyurethane)	Straight stents (polyethylene)	P value
Vancomycin-resistant enterococci (VRE)	18/125 (14.4%)	12/94 (12.8%)	0.728

(Continued)

Table 2. (Continued)

Bacteria			
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	2/2 (100%)	1/3 (33.3%)	0.400
ESBL-producing <i>Enterobacteriaceae</i> , resistant to 3 of 4 major antibiotic classes ^S (3MRGN)	17/129 (13.2%)	15/101 (14.9%)	0.716
Carbapenemase producing <i>Enterobacteriaceae</i> , resistant to 4 of 4 major antibiotic classes ^S (4MRGN)	1/129 (0.8%)	0/101 (0%)	1.000
Azole-resistant <i>Candida</i> species	25/80 (31.3%)	23/66 (34.8%)	0.645

Abbreviations: MRGN = multi-drug resistant Gram-negatives

^Scephalosporins, acylaminopenicillins, fluoroquinolones, and carbapenems

*The complete list of species included (number of isolates in brackets, in descending order of frequency):

Enterococcus faecalis (107), *Candida albicans* (103), *Escherichia coli* (89), *Enterococcus faecium* (63), *Streptococcus anginosus* (36), *Enterobacter cloacae* (31), *Klebsiella oxytoca* (24), *Candida glabrata* (23), *Enterococcus casseliflavus* (17), *Enterococcus avium* (15), *Pseudomonas aeruginosa* (12), *Enterococcus gallinarum* (11), *Hafnia alvei* (11), *Proteus vulgaris* (11), *Streptococcus parasanguinis* (11), *Staphylococcus epidermidis* (10), *Streptococcus oralis/mitis* (10), *Prevotella melaninogenica* (9), *Citrobacter braakii* (6), *Morganella morganii* (6), *Staphylococcus haemolyticus* (6), *Bacteroides vulgatus* (5), *Bacteroides fragilis* (5), *Candida kefyr* (5), *Candida tropicalis* (5), *Staphylococcus aureus* (5), *Streptococcus constellatus* (5), *Veillonella parvula* (5), *Citrobacter freundii* (4), *Lactobacillus rhamnosus* (4), *Neisseria subflava* (4), *Raoultella planticola* (4), *Streptococcus gallolyticus ssp. gallolyticus* (4), *Streptococcus salivarius ssp. salivarius* (4), *Actinomyces odontolyticus* (3), *Bifidobacterium ssp.* (3), *Enterococcus durans* (3), *Enterococcus hirae* (3), *Haemophilus parainfluenzae* (3), *Serratia marcescens* (3), *Candida colliculosa* (2), *Candida krusei* (2), *Candida parapsilosis* (2), *Citrobacter koseri* (2), *Citrobacter youngae* (2), *Cronobacter sakazakii* (2), *Enterobacter aerogenes* (2), *Lactobacillus plantarum* (2), *Prevotella buccae* (2), *Rothia mucilaginosa* (2), *Streptococcus sanguinis* (2), *Acinetobacter baumannii* (1), *Abiotrophia defectiva* (1), *Actinomyces viscosus* (1), *Aeromonas hydrophila* (1), *Bacillus pumilus* (1), *Bacteroides uniformis* (1), *Bacteroides ovatus* (1), *Bacteroides stercoris* (1), *Bacteroides thetaiotaomicron* (1), *Candida dubliniensis* (1), *Candida guilliermondii* (1), *Candida lambica* (1), *Candida norvegensis* (1), *Clostridium perfringens* (1), *Corynebacterium aurimucosum* (1), *Corynebacterium bovis* (1), *Corynebacterium pseudodiphthericum* (1), *Corynebacterium striatum* (1), *Cryptococcus huminocola* (1), *Cryptococcus laurentii* (1), *Enterobacter amnigenus* (1), *Escherichia hermannii* (1), *Gemella sanguis* (1), *Lactobacillus casei* (1), *Lactobacillus acidophilus* (1), *Lactococcus garvieae* (1), *Leifsonia aquatica* (1), *Microbacter flavescens* (1), *Moraxella osloensis* (1), *Mycobacterium avium* (1), *Parabacteroides distasonis* (1), *Pediococcus pentosaceus* (1), *Prevotella denticola* (1), *Prevotella oris* (1), *Propionibacterium avidum* (1), *Propionibacterium acnes* (1), *Providencia rettgeri* (1), *Pseudomonas stutzeri* (1), *Ralstonia insidiosa* (1), *Raoultella ornithinolytica* (1), *Rhizobium radiobacter* (1), *Saccharomyces cerevisiae* (1), *Salmonella ssp.* (1), *Staphylococcus capitis* (1), *Staphylococcus saprophyticus* (1), *Staphylococcus vitulinus* (1), *Streptococcus suis* (1), *Streptococcus equinus ssp. zooepidemicus* (1), *Streptococcus gallolyticus ssp. pasteurianus* (1), *Streptococcus infantarius ssp. coli* (1), *Streptococcus pneumoniae* (1), *Trueperella bernardiae* (1), *Vibrio alginolyticus* (1), *Yersinia pseudotuberculosis* (1).

doi:10.1371/journal.pone.0155479.t002

(40.8% vs. 26.3%, $P = 0.032$), and *Pseudomonas aeruginosa* (1.3% vs. 8.8%, $P = 0.035$), respectively, comparing malignant and benign biliary strictures (S1 Table).

Matching rate of blood cultures and stent samples

In 42 of the 120 patients, a total of 58 blood cultures were obtained, of which 30 were positive. In 17 of these (56.7%; 95% CI: 37.4% to 74.5%), there was agreement with the microbiological results from biliary stents regarding the detected pathogen (the microbial species involved were *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus avium*, *Streptococcus anginosus*, *Escherichia coli*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Candida albicans*), and in 11 there was complete agreement with the respective phenotypic resistance profiles.

Five of 120 patients (4.2%) died due to biliary infections with sepsis. Four of these patients were liver transplant recipients, and one patient suffered from metastatic gallbladder carcinoma. Blood cultures detected *Enterobacteriaceae* (*Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Serratia marcescens*), Enterococci (*Enterococcus faecium*) and *Pseudomonas*




Fig 4. Scatter plot of stent duration in place (in days) vs. number of detected microorganisms.

doi:10.1371/journal.pone.0155479.g004

aeruginosa as triggering pathogens. Antimicrobial treatment was performed by carbapenems and linezolid according to the results of the microbiological susceptibility testing.

Time dependency of stent colonization

The time-dependent graphical representation of stent colonizers grouped by enterococci, *Enterobacteriaceae*, *Candida* species, and streptococci showed a significantly different distribution of enterococci versus *Candida* spp. ($P < 0.001$), and enterococci versus streptococci ($P = 0.005$), respectively (log-rank test) (Fig 5).




Fig 5. Stent duration in place (in days) versus microbiological isolates from sonicated stent fluids, grouped by predominant enterococci, *Enterobacteriaceae*, *Candida* spp., and streptococci.

doi:10.1371/journal.pone.0155479.g005

Stent colonization with respect to antibiotic therapy

Stent colonization differed significantly with respect to the proportion of *Candida* species (63% vs. 46.7%, $P = 0.023$) in patients receiving prolonged antibiotic therapy (Fig 6). In the other groups, no significant differences were found.

Antimicrobial resistance profiles

Antimicrobial resistance profiles, grouped by *Enterococcus faecalis*, *Enterococcus faecium*, streptococci, *Escherichia coli*, anaerobes, *Candida albicans*, and non-albicans *Candida* (NAC) species, are distributed in Fig 7. The rate of vancomycin resistance among enterococci was 13.7% (30 of 219 isolates; 95% CI: 9.4% to 19%; 0.9% in *Enterococcus faecalis* and 28.6% in *Enterococcus faecium*). The proportion of ESBL producers among *Enterobacteriaceae* with co-resistance to ciprofloxacin was 13.9% (32/230; 95% CI: 9.7% to 19.1%). There was only one patient with the detection of carbapenem-resistant isolates due to known intestinal colonization by a *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Klebsiella pneumoniae* strain, which was also detected on a biliary stent. Azole-resistant *Candida* species accounted for 32.9% (48/146; 95% CI: 25.3% to 41.1%) of the isolates.

Independent predictors for colonization with enterococci and *Candida* spp.

Logistic regression analysis (using the following independent variables: age, gender, malignant biliary strictures, preceding liver transplantation, presence of diabetes mellitus, repeated ERC, prolonged antibiotic therapy >48 hours, and length of hospital stay >7 days) revealed that repeated ERC intervention was an independent predictor for the occurrence of enterococci (odds ratio [OR] 9.75; 95% CI: 1.24 to 76.43), and presence of a malignant biliary stricture was an independent predictor for the occurrence of *Candida* spp. (OR 2.55; 95% CI: 1.08 to 6.05).




Fig 6. Distribution of bacterial and fungal species depending on the use of antibiotics. Stent colonization differed significantly with respect to the proportion of *Candida* species (46.7% vs. 63%, $P = 0.023$) in patients receiving prolonged antibiotic therapy.

doi:10.1371/journal.pone.0155479.g006




Fig 7. In vitro antibiotic susceptibilities of bacterial and fungal isolates, grouped by *Enterococcus faecalis*, *Enterococcus faecium*, streptococci, *Escherichia coli*, *Candida albicans*, and non-albicans *Candida* (NAC) species. Minimum inhibitory concentrations (MICs) were determined employing Industrial Organization for Standardization (ISO) 20766–1 or E-test, and the results were interpreted according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (www.eucast.org, 2015 edition).

doi:10.1371/journal.pone.0155479.g007

Discussion

In this study, 213 stents from 120 patients with the detection of 95 different bacteria and 13 different fungal species were included in the final analysis. Compared to previous analyses with a similar design and methodology [17–20,24], our study is distinguished by the large sample size; the use of sonication facilitating a better release of pathogens from the biofilm on the inner surface of the stents [10,29,30]; the application of MALDI-TOF mass spectrometry for precise identification of microorganisms; and a detailed antimicrobial susceptibility analysis involving 28 antibiotics and seven antifungal agents.

Our results reveal the highest detection rate for both enterococci (79.3% of all stents) and *Candida* species (55.9% of all stents) of all studies investigating patients with biliary stents [10,17,19,20,23–27,35–37]. The occurrence of both pathogen groups was significantly associated with an increased indwelling time of stents (Fig 5). Moreover, previous antibiotic therapy seems to exert significant selective pressure as also reported elsewhere [25,27]. Thus, the stent colonization differed significantly with respect to the proportion of *Candida* species (46.7% vs. 63%, $P = 0.023$) in patients receiving earlier prolonged antibiotic therapy. Unquestionably, this pathogen shift has clinical relevance, as conventional doctrines regarding the microbiology of the biliary tract describe a predominance of *Enterobacteriaceae* and anaerobes, followed by enterococci and streptococci [38,39].

Preceding studies have shown a clear association between biliary stent insertion and changes in the spectrum of pathogens in the bile toward enterococci [10,23,36], as well as the increased incidence of bacterial and fungal colonization associated with pre-operative biliary drainage [37]. In a study performed by Weber et al. in Germany, enterococci were by far the most prevalent genera, reaching detection rates of >70% in patients with stent-associated cholangitis [23].

Thus, the high proportion of enterococcal species of 79.3% in our study is in line with previous reports, revealing that samples collected from patients with stents had a significantly higher incidence of *Enterococcus spp.* compared to bile samples from patients without stents, corroborating a “stent tropism” of enterococci [10,23,36]. Furthermore, the number of enterococci isolated from blood cultures appeared to be higher in stent-associated cholangitis episodes [23]. In this context, repeated ERC intervention was an independent predictor for the occurrence of enterococcal species (OR 9.75) in our study. The well-described risk factors of *Candida* in bile include biliary stenting, malignant strictures, and repeated interventions [23,26]. In such patients, prolonged antibiotic treatment apparently facilitates biliary colonization by *Candida spp.* [26,27], as also shown in our study. From a clinical point of view, the detection of significantly more *Candida spp.* (as well as viridans group streptococci) in patients with malignant disease may also reflect a certain degree of tumor-associated immunological dysfunction.

The majority of stent extractions were performed electively, and therefore, blood cultures were collected only in patients presenting with acute cholangitis or general signs of infection. Because the matching rate of blood cultures and stent isolates was 56.7% in our study, we assume that corresponding shifts in the biliary pathogen spectrum toward enterococci and *Candida spp.* may be clinically relevant in the case of stent-associated acute cholangitis. However, Schneider et al. already pointed out that the hypothesis that microorganisms isolated from the biofilms on biliary stent surfaces are similar to microorganisms in the bile fluid still has to be proven [10], as concomitant bile cultures were not systematically collected in most available studies and systematic microbiological typing was omitted. Negm et al. concluded in a recent study of endoscopically obtained bile aspirates that all microorganisms found in positive blood cultures were also found in bile samples [26], indicating that biliary culture results alone are as effective as positive blood cultures. In the literature, the clinical relevance of endoscopically performed bile collection for microbiological analysis is discussed controversially [10,26,35–37]. In a study performed by Park et al. in Korea, in 258 bacteremic cholangitis episodes, complete agreement with blood cultures was observed only in 31% of the bile samples [35]. Fifty percent of the bile specimens showed partial agreement with the blood culture findings, and 19% of the bile cultures revealed completely different microorganisms compared to the blood cultures analyzed. The degree of coincidence between the bile and blood cultures for *Escherichia coli*, *Klebsiella spp.*, enterococci, and streptococci was 71%, 53%, 35%, and 27%, respectively [35]. In our setting, the risk of cholangitis was significantly higher in patients with stent occlusion (38.5% vs. 9.1%, $P < 0.001$). In the study performed by Schneider et al., biliary stents occluded after a median indwelling time of 70 days [10]. However, stent occlusion resulted in cholangitis or cholestasis in only 35% of the cases. Thus, stent occlusion is not always associated with clinical symptoms.

The question of the optimal stent surface with regard to the prevention of occlusion has not yet been answered satisfactorily, whereby an advantage for Teflon™ (polytetrafluorethylene) compared to other plastics could be demonstrated [6]. Several studies have shown that antimicrobial coatings on medical devices are effective against the formation of microbial biofilms [10]. Therefore, the use of special coatings, such as diamond-like carbons (DLC) or silver-nanoparticles, seems to be a promising approach for reducing biofilm formation on medical implants [40,41]. On the other hand, there has been no evidence so far that modified surfaces offer effective protection against the apparently growing threat of colonization by enterococci and *Candida* species.

Regarding antimicrobial resistance profiles, in our environment, resistance rates to vancomycin in enterococci (0.9% in *E. faecalis*, and 28.6% in *E. faecium*), the rate of co-resistance to ciprofloxacin in ESBL-producing *Enterobacteriaceae* (13.9%), and the resistance rate to carbapenems in *Enterobacteriaceae* (0.4%) were still within feasible ranges. However, taking into

account the azole resistance rate of 32.9%, significant failure rates of fluconazole-based empirical antifungal therapies for *Candida* infections have to be considered. It is well known that numerous interventional ERC procedures accompanied by antibiotic therapy predispose for increased antimicrobial resistance in patients with acute cholangitis [25,27], and enterococcal species are often involved in this process [42,43]. Therefore, adequate microbiological diagnosis is essential and should include analysis of the extracted stents.

Multi-drug resistance is generally on the rise, particularly among *Enterobacteriaceae* [44–47]. Regarding the detection of carbapenem-resistant *Enterobacteriaceae* (CRE) in a single patient in our study, it is important to keep in mind that biliary colonization with CRE may have enormous clinical relevance in certain patient groups, such as liver transplant recipients [48]. Taking into consideration existing hygiene recommendations for the clinical management of affected patients in Germany, we propose active surveillance and stringent contact isolation precautions in hospitals, particularly in the endoscopy unit [49]. Invasive procedures as well as the use of antibiotics should be limited to clear medical indications.

In the overall assessment, our study has limited representativeness due to its monocentric design, and it displays several limitations: Firstly, the contamination of samples during endoscopic retrieval of stents cannot be excluded. Secondly, the choice and indwelling times of polyethylene or polyurethane stents inserted in the bile duct were arbitrary. Therefore, the timing of stent extraction and the indications for stent placement were not standardized. Thirdly, clinical selection bias cannot be excluded because it was a non-randomized study, and the results of the microbiological analysis are certainly influenced by the use of antimicrobial agents.

Conclusions

We conclude that enterococci and *Candida* species play an important role in the microbial colonization of biliary stents. Therefore, empirical antimicrobial treatment of stent-associated cholangitis should be guided toward enterococci, *Enterobacteriaceae*, streptococci, anaerobes, and *Candida*. To determine causative pathogens, an accurate microbiological analysis of the extracted stent(s) may be helpful. Assessing the presence of pathobionts versus symbionts in the biliary tract is an important task of future clinical studies.

Supporting Information

S1 Dataset. The study data base is available for download.
(XLSX)

S1 Table. Microorganisms isolated from biliary stents in relation to disease and stent characteristics.
(DOC)

Acknowledgments

The authors would like to thank Annett Hennig-Rolle and Heiko Kranz (both Leipzig University Hospital, Germany) for their helpful assistance. We acknowledge support from the German Research Foundation (DFG) and Universität Leipzig within the program of Open Access Publishing.

Author Contributions

Conceived and designed the experiments: CL ACR. Performed the experiments: KW AM CL JF JM AH. Analyzed the data: CL KW AM NL TB ACR. Contributed reagents/materials/

analysis tools: AM JM ACR. Wrote the paper: CL. Critical revision of the manuscript: CL KW JF AM NL TB JM AH ACR.

References

1. Wenderoth DF, Ferslev B, Macarri G, Molinari G, Lünsdorf H, Timmis KN. Leitbacteria of microbial bio-film communities causing occlusion of biliary stents. *Environ Microbiol* 2003; 5: 859–66 PMID: [14510839](#)
2. Dumonceau JM, Tringali A, Blero D, Devière J, Heresbach D, Costamagna G, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy* 2012; 44: 277–98 doi: [10.1055/s-0031-1291633](#) PMID: [22297801](#)
3. Baron TH Sr., Davee T. Endoscopic management of benign bile duct strictures. *Gastrointest Endosc Clin N Am* 2013; 23: 295–311 doi: [10.1016/j.giec.2013.01.001](#) PMID: [23540962](#)
4. Groen AK, Out T, Huibregtse K, Delzenne B, Hoek FJ, Tytgat GN. Characterization of the content of occluded biliary endoprotheses. *Endoscopy* 1987; 19: 57–9 PMID: [3106022](#)
5. Speer AG, Cotton PB, Rode J, Seddon AM, Neal CR, Holtgon J, et al. Biliary stent blockage with bacterial biofilm. A light and electron microscopy study. *Ann Intern Med* 1988; 108: 546–53 PMID: [2450501](#)
6. Dowidar N, Kolmos HJ, Matzen P. Experimental clogging of biliary endoprotheses. Role of bacteria, endoprosthesis material, and design. *Scand J Gastroenterol* 1992; 27: 77–80 PMID: [1736347](#)
7. Zhang H, Tsang TK, Jack CA. Bile glycoprotein mucin in sludge occluding biliary stent. *J Lab Clin Med* 2003; 142: 58–65 PMID: [12878987](#)
8. Lawrence C, Romagnuolo J, Payne KM, Hawes RH, Cotton PB. Low symptomatic premature stent occlusion of multiple plastic stents for benign biliary strictures: comparing standard and prolonged stent change intervals. *Gastrointest Endosc* 2010; 72: 558–63 doi: [10.1016/j.gie.2010.05.029](#) PMID: [20638060](#)
9. Boulay BR, Gardner TB, Gordon SR. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. *J Clin Gastroenterol* 2010; 44: 452–5 doi: [10.1097/MCG.0b013e3181d2ef06](#) PMID: [20179612](#)
10. Schneider J, Hapfelmeier A, Fremd J, Schenk P, Obermeier A, Burgkart R, Forkl S, et al. Biliary Endoprosthesis: A Prospective Analysis of Bacterial Colonization and Risk Factors for Sludge Formation. *PLOS ONE* 2014; 9: e110112 doi: [10.1371/journal.pone.0110112](#) PMID: [25314593](#)
11. van Berkel AM, Boland C, Redekop WK, Bergman JJ, Groen AK, Tytgat GN, et al. A prospective randomized trial of Teflon versus polyethylene stents for distal malignant biliary obstruction. *Endoscopy* 1998; 30: 681–86 PMID: [9865556](#)
12. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. *Lancet* 1992; 340: 1488–92 PMID: [1281903](#)
13. Halm U, Schiefke I, Fleig WE, Mössner J, Keim V. Ofloxacin and Ursodeoxycholic Acid versus Urso-deoxycholic Acid Alone to Prevent Occlusion of Biliary Stents: A Prospective, Randomized Trial. *Endoscopy* 2001; 33: 491–4 PMID: [11437041](#)
14. Leung JW, Ling TK, Kung JL, Vallance-Owen J. The role of bacteria in the blockage of biliary stents. *Gastrointest Endosc* 1988; 34: 19–22 PMID: [3280393](#)
15. van Berkel AM, van Marle J, Groen AK, Bruno MJ. Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. *Endoscopy* 2005; 37: 729–34 PMID: [16032491](#)
16. Donelli G, Guaglianone E, Di Rosa R, Fiocca F, Basoli A. Plastic biliary stent occlusion: factors involved and possible preventive approaches. *Clin Med Res* 2007; 5: 53–60 PMID: [17456835](#)
17. Di Rosa R, Donelli G, Penni A, Penni A, Salvatori FM, Fiocca F, et al. A microbiological and morphological study of blocked biliary stents. *Microb Ecol Health Dis* 1999; 11: 84–8
18. Coene PP, Groen AK, Cheng J, Out MM, Tytgat GN, Huibregtse K. Clogging of biliary endoprotheses: a new perspective. *Gut* 1990; 31: 913–7 PMID: [2387517](#)
19. Guaglianone E, Mastrantonio P, Di Rosa R, Babini V, Mastrantonio P, Donelli G. Role of multispecies microbial biofilms in the occlusion of biliary stents. *Microb Ecol Health Dis* 2008; 20: 207–9
20. Guaglianone E, Cardines R, Vuotto C, Di Rosa R, Babini V, Mastrantonio P, Donelli G. Microbial biofilms associated with biliary stent clogging. *FEMS Immunol Med Microbiol* 2010; 59: 410–20 doi: [10.1111/j.1574-695X.2010.00686.x](#) PMID: [20482630](#)
21. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents* 2010; 35: 322–32 doi: [10.1016/j.ijantimicag.2009.12.011](#) PMID: [20149602](#)

22. van Merode AEJ, van der Mei HC, Busscher HJ, Krom BP. Influence of Culture Heterogeneity in Cell Surface Charge on Adhesion and Biofilm Formation by *Enterococcus faecalis*. *J Bacteriol* 2006; 188: 2421–6 PMID: [16547028](#)
23. Weber A, Schneider J, Wagenpfeil S, Winkle P, Riedel J, Wantia N, et al. Spectrum of pathogens in acute cholangitis in patients with and without biliary endoprosthesis. *J Infect* 2013; 67: 111–21 doi: [10.1016/j.jinf.2013.04.008](#) PMID: [23603487](#)
24. Basioukas P, Vezakis A, Zarkotou O, Fragulidis G, Themeli-Digalaki K, Rizos S, et al. Isolated microorganisms in plastic biliary stents placed for benign and malignant diseases. *Ann Gastroenterol* 2014; 27: 399–403 PMID: [25331687](#)
25. Schneider J, De Waha P, Hapfelmeier A, Feihl S, Römmler F, Schlag C, et al. Risk factors for increased antimicrobial resistance: a retrospective analysis of 309 acute cholangitis episodes. *J Antimicrob Chemother* 2014; 69: 519–25 doi: [10.1093/jac/dkt373](#) PMID: [24084640](#)
26. Negm AA, Schott A, Vonberg RP, Weismueller T, Schneider AS, Kubicka S, et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. *Gastrointest Endosc* 2010; 72: 285–91
27. Gotthardt DN, Weiss KH, Rupp C, Bode K, Eckerle I, Rudolph G, et al. Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. *Endoscopy* 2013; 45: 890–6 doi: [10.1055/s-0033-1344713](#) PMID: [24165814](#)
28. Rupp C, Bode KA, Chahoud F, Wannhoff A, Friedrich K, Weiss KH, et al. Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis. *BMC Infect Dis* 2014; 14: 562 doi: [10.1186/s12879-014-0562-8](#) PMID: [25338733](#)
29. Rieger UM, Pierer G, Luscher NJ, Trampuz A. Sonication of removed breast implants for improved detection of subclinical infection. *Aesthetic Plast Surg* 2009; 33: 404–8 doi: [10.1007/s00266-009-9333-0](#) PMID: [19322605](#)
30. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. *N Engl J Med* 2007; 357: 654–63 PMID: [17699815](#)
31. EUCAST, 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0 (bacteria) and version 8.0 (fungi). Available from: <http://www.eucast.org>; 1 Jan 2015. Accessed 12 December 2015
32. Leverstein-van Hall MA, Fluit AC, Paauw A, Box AT, Brisse S, Verhoef J. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant *Escherichia coli* and *Klebsiella* spp. *J Clin Microbiol* 2002; 40: 3703–11 PMID: [12354869](#)
33. Moter A, Göbel UB. Fluorescence in situ hybridization (FISH) for direct visualization of microorganisms. *J Microbiol Methods* 2000; 41: 85–112 PMID: [10991623](#)
34. Mallmann C, Siemoneit S, Schmiedel D, Petrich A, Gescher DM, Halle E, et al. Fluorescence in situ hybridization to improve the diagnosis of endocarditis: a pilot study. *Clin Microbiol Infect* 2010; 16: 767–73 doi: [10.1111/j.1469-0691.2009.02936.x](#) PMID: [19694763](#)
35. Park JW, Lee JK, Lee KT, Lee KH, Sung YK, Kang CI. How to interpret the bile culture results of patients with biliary tract infections. *Clin Res Hepatol Gastroenterol* 2014; 38: 300–9 doi: [10.1016/j.clinre.2014.02.005](#) PMID: [24674840](#)
36. Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. *Gastrointest Endosc* 2002; 56: 885–9 PMID: [12447303](#)
37. Jethwa P, Breuning E, Bhati C, Buckles J, Mirza D, Bramhall S. The microbiological impact of pre-operative biliary drainage on patients undergoing hepato-biliary-pancreatic (HPB) surgery. *Aliment Pharmacol Ther* 2007; 25: 1175–80 PMID: [17451563](#)
38. Sheen-Chen S, Chen W, Eng H, Sheen C, Chou F, Cheng Y, et al. Bacteriology and antimicrobial choice in hepatolithiasis. *Am J Infect Control* 2000; 28: 298–301 PMID: [10926707](#)
39. Brook I. Aerobic and anaerobic microbiology of biliary tract disease. *J Clin Microbiol* 1989; 27: 2373–75 PMID: [2584384](#)
40. Roy RK, Lee KR. Biomedical applications of diamond-like carbon coatings: a review. *J Biomed Mater Res B Appl Biomater* 2007; 83: 72–84 PMID: [17285609](#)
41. Wen W, Ma LM, He W, Tang XW, Zhang Y, Wang X, Liu L, et al. Silver-nanoparticle-coated biliary stent inhibits bacterial adhesion in bacterial cholangitis in swine. *Hepatobiliary Pancreat Dis Int* 2016; 15: 87–92 PMID: [26818548](#)
42. Lübbert C, Rodloff AC, Hamed K. Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE). *Infect Dis Ther* 2015; 4: 259–71 doi: [10.1007/s40121-015-0072-z](#) PMID: [26168986](#)

43. Lübbert C, Wilhelms D, Worlitzsch D, Ettrich TJ, Behl S, Seufferlein T. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin—first experiences from the EU-CORE registry study (European Cubicin[®] Outcomes Registry and Experience)]. *Z Gastroenterol* 2012; 50: 373–81 doi: [10.1055/s-0031-1282031](https://doi.org/10.1055/s-0031-1282031) PMID: [22430297](https://pubmed.ncbi.nlm.nih.gov/22430297/)
44. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β -lactamases in the community: towards the globalization of CTX-M. *Clin Microbiol Rev* 2013; 26: 744–58 doi: [10.1128/CMR.00023-13](https://doi.org/10.1128/CMR.00023-13) PMID: [24092853](https://pubmed.ncbi.nlm.nih.gov/24092853/)
45. Kuster SP, Hasse B, Hübner V, Bansal V, Zbinden R, Ruef C, et al. Risk factors for infections with extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* at a tertiary care university hospital in Switzerland. *Infection* 2010; 38: 33–40 doi: [10.1007/s15010-009-9207-z](https://doi.org/10.1007/s15010-009-9207-z) PMID: [20108162](https://pubmed.ncbi.nlm.nih.gov/20108162/)
46. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β -lactamase production in *Enterobacteriaceae* bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother* 2007; 60: 913–20 PMID: [17848376](https://pubmed.ncbi.nlm.nih.gov/17848376/)
47. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Gormican M, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis* 2013; 13: 785–96 doi: [10.1016/S1473-3099\(13\)70190-7](https://doi.org/10.1016/S1473-3099(13)70190-7) PMID: [23969216](https://pubmed.ncbi.nlm.nih.gov/23969216/)
48. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing *Klebsiella pneumoniae* is associated with high infection rates and excess mortality: a case-control analysis. *Infection* 2014; 42: 309–16 doi: [10.1007/s15010-013-0547-3](https://doi.org/10.1007/s15010-013-0547-3) PMID: [24217959](https://pubmed.ncbi.nlm.nih.gov/24217959/)
49. KRINKO. Hygienemaßnahmen bei Infektionen oder Besiedelung mit multiresistenten gramnegativen Stäbchen. *Bundesgesundheitsbl* 2012; 55: 1311–54